Numerical chromosomal anomalies in latent adenocarcinomas of the prostate

Prostate

Volumn 38, Issue 2, 1999, Pages 92-99

  Erbersdobler, Andreas ^a   Bardenhagen, Petra ^a   Henke, Rolf Peter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Autopsy; Hybridization; Ploidy; Prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; AUTOPSY; CANCER GRADING; CHROMOSOME 10; CHROMOSOME 17; CHROMOSOME 7; CHROMOSOME ABERRATION; DISOMY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 7; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; X CHROMOSOME; Y CHROMOSOME;

EID: 0032923964     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990201)38:2<92::AID-PROS2>3.0.CO;2-6     Document Type: Article

References (42)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA 1997;47:5-27.
2. Silverberg E. Statistical and epidemiologic data on urologic cancer. Cancer [Suppl] 1987;60:692-717.
3. Von Eschenbach AC. The biologic dilemma of early carcinoma of the prostate. Cancer 1996;78:326-329.
4. Dhom G. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983;106:210-218.
5. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992;23:211-222.
6. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med 1995; 333:1401-1405.
7. Isaacs JT. Molecular markers for prostate cancer metastasis: developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol 1997;150:1511-1521.
8. Henke R-P, Krüger E, Ayhan N, Hübner D, Hammerer P. Frequency and distribution of numerical chromosomal aberrations in prostatic cancer. Hum Pathol 1994;25:476-484.
9. Steilen H, Ketter R, Romanakis K, Zwergel T, Unteregger G, Bonkhoff H, Seitz G, Ziegler M, Zang KD, Wullich B. DNA aneuploidy in prostatic adenocarcinoma: a frequent event as shown by fluorescence in situ DNA hybridization. Hum Pathol 1994;25:1306-1313.
10. Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Löhrs U. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 1994;54: 4472-4480.
11. Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB. Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 1994;152:1157-1162.
12. König JJ, Teubel W, Romijn JC, Schröder FH, Hagemeijer A. Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol 1996;27:720-727.
13. Hopman AHN, Ramaekers FCS, Vooijs GP. Interphase cytogenetics of solid tumours. In: Polak JM, McGee JO'D, editors. In situ hybridization. Principles and practice. Oxford: Oxford University Press; 1990. p 165-186.
14. Poddighe PJ, Ramaekers FCS, Hopman AHN. Interphase cytogenetics of rumours. J Pathol 1992;166:215-224.
15. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
16. Gleason DF, Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of prostate carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea & Febiger; 1977. p 171-197.
17. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
18. Hedrik L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989;13:389-396.
19. Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, Lieber MM, Jenkins RB. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol 1996;149:1193-1199.
20. Erbersdobler A, Gürses N, Henke R-P. Numerical chromosomal changes in high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma. Pathol Res Pract 1996;192: 418-427.
21. Rich AR. On the frequency of occurrence of occult carcinoma of the prostate. J Urol 1935;33:215-223.
22. Gaynor EP. Zur Frage des Prostatakrebses. Virchows Arch 1938; 301:602-652.
23. Franks LM. Latent carcinoma of the prostate. J Path Bact 1954; 68:603-616.
24. Halpert B, Schmalhorst WR. Carcinoma of the prostate in patients 70 to 79 years old. Cancer 1966;19:695-698.
25. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P. Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 1980;65:311-316.
26. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid H-P. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-938.
27. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate: morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-2318.
28. Meikle AW, Smith JA. Epidemiology of prostate cancer. Urol Clin North Am 1990;17:709-718.
29. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;1:60-63.
30. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-294.
31. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-1063.
32. McNeal JH. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 1992;23:258-266.
33. Grignon DJ, Sakr WA. Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J Cell Biochem 1994;19:267-269.
34. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 1992;69:2293-2299.
35. Watanabe M, Imai H, Kato H, Shiraishi T, Ushijima T, Nagao M, Yatani R. Microsatellite instability in latent prostate cancers. Int J Cancer 1996;69:394-397.
36. Sandberg AA. Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 1992;23:368-380.
37. Micale MA, Sanford JS, Powell IJ, Sakr WA, Wolman SR. Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma: paraffin FISH vs. metaphase analysis. Cancer Genet Cytogenet 1993;69:7-12.
38. Alers JC, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast TH, van Dekken H. Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer 1995;12:241-250.
39. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995;55:5408-5414.
40. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, Scardino PT. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 1994;151:1301-1307.
41. Epstein JI. Prostatic intraepithelial neoplasia. Adv Anat Pathol 1994;1:123-134.
42. Erbersdobler A, Hammerer P, Huland H, Henke R-P. Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. J Urol 1997;158:1594-1598.